Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studies
The ENRICH study examined BRII-179 as a priming therapy before administering elebsiran and PEG-IFNα.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance